RCEL - AVITA Medical Inc. Debt to Book Capitalization Ratio

Corporate company logo of AVITA Medical, Inc. (RCEL)

The slowdown in profitability for AVITA Medical, Inc. (RCEL) is driven by prolonged waits for US regulatory approvals and marketing expenses. Meanwhile, AVITA Medical, Inc. (RCEL) generates revenue through the sale of tissue regeneration consumables, creating a high-margin recurring payment stream. The current figure stands at 0.00. The stock price chart below reflects the price action of an asset reliant on a complex transportation system for high-tech medical kits.

AVITA Medical, Inc. - RCEL Debts to Book Capitalization (period 07/04/2022 - 10/28/2026)
Flagship merchandise of AVITA Medical Inc

High margins on consumables for AVITA Medical skin regeneration systems create a foundation for sustainable growth, although debt leverage may limit this potential. The ratio of borrowed funds to the book value of assets determines the business's degree of dependence on creditors, allowing investors to identify hidden accumulation of liabilities that threaten the company's financial stability through the dynamics of the debt-to-book capitalization metric.

Competitors of AVITA Medical, Inc.

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|TCMD - Debt to Book Capital|SANUWAVE - Debts to Book Capitalization|Outset Medical Inc (OM) - Debts to Net Assets|Debts to Book Capitalization ELMD|Debt to Book Value LENSAR Inc (LNSR)|Profound Medical Corp. (PROF) - Debt to Book Value|Debt to Net Assets Ratio BDMD (bairdmed.com)|EDAP TMS - Debt to Book Capitalization Ratio|Debt to Book Value Apyx Medical Corp APYX|ICCM (IceCure Medical, Ltd.) - Debts to Book Capitalization|LUNG - Debts to Book Value|Debts to Book Capitalization telabio.com|CytoSorbents Corporation (CTSO) - Debt to Book Value Ratio|SRTS: Debts to Book Capitalization|Debts to Net Assets Zynex Medical|Debts to Book Capitalization ECOR (electroCore, Inc.)|Debt to Book Value vicarioussurgical.com (RBOT)|Debts to Book Capitalization IINN (Inspira Technologies)|seastarmedical.com - Debts to Book Capitalization|IRIX - Debt to Book Capitalization Ratio|Intelligent Bio Solutions (INBS) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio